Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
72 CAR T-cell therapy directly targets tumor surface antigens via engineered CARs, completely bypassing the tumor cell-intrinsic MHC class I antigen presentation pathway, whereas CAR-NK cell therapy integrates CAR-directed cytotoxicity with the innate missing-self recognition of NK cells, enabling efficient elimination of tumor cells with downregulated or absent MHC class I expression and thereby directly addressing resistance mechanisms
Unlike oral supplements, which face the gauntlet of our digestive system (and often get broken down, resulting in as little as 20-50% absorption), intravenous delivery bypasses the gut entirely
Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP
Naunyn-Schmiedeberg's Arch Pharmacol 399 , 31593188 (2026)
US$ 24.38
US$ 25.11
US$ 24.50
US$ 20.04
US$ 29.73
US$ 21.23
US$ 21.41
US$ 23.09
